Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00586651 | Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis | PHASE2 | COMPLETED | 39 | — | — | Dec 1, 2007 | Sep 1, 2010 | Oct 8, 2015 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| lestaurtinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| lestaurtinib | DRUG | 60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration |
Inclusion Criteria: * The patient has polycythemia vera (PV) or essential thrombocytosis (ET). * The patient has a detectable JAK2 V617F mutation. * Patients with PV have at least 1 of the following risk factors: 1. neutrophil count greater than 7000/mm3 2. receiving hydroxyurea treatment * Pa...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Protagonist Therapeutics, Inc. | PTGX | 2 | PHASE3 | Rusfertide, Open-label rusfertide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE2 | sapablursen |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-3405 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Novartis AG Sponsored ADR | NVS | 1 | — | Undisclosed |